Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (8 ops.)
Latest filing published 03 Oct 2022 for Biohaven Pharmaceutical Holding Co Ltd., €765k.
Insider track record
Disclosed buys
0
Disclosed sells
8
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
John Tilton: trading record in brief
John Tilton (chief executive) discloses dealings in Biohaven Pharmaceutical Holding Co Ltd. to SEC (Form 4). Over a trading history stretching from 9 May 2017 to 3 October 2022, the count stands at 27 filings.
No open-market purchase appears, only 8 sales worth €4.6M. Besides market trades, the filings include 6 share grants and 10 option exercises.
The newest entry dates from 3 October 2022: a transaction of €244k, in Biohaven Pharmaceutical Holding Co Ltd. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to John Tilton
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
5,068 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006956:0
1,250 shares0Common SharesSEC:0001562180-22-000357:0
1,250 shares0Common SharesSEC:0001562180-21-007304:0
3 of 3 declarations
